ABEO Abeona Therapeutics Inc.

Abeona Therapeutics’ Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Leadership Plan

Abeona Therapeutics’ Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Leadership Plan
EN
06/10/2020

Underlying

ABEOAbeona Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Abeona Therapeutics Inc.

 PRESS RELEASE
Free
ABEO Abeona Therapeu...

Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Re...

Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million Cash resources totaled approximately $225 million as of June 30, 2025 CLEVELAND, July 02, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $155 million on June 27, 2025. Including net proceeds from the sale of the PRV, the Company reported that unaudited cash, cash equivalents, restricted cash and short-term investments as of June 30, 2025 were approxi...

July 2, 2025 1 EN
 PRESS RELEASE
Free
ABEO Abeona Therapeu...

Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics ...

Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy Abeona will receive a license payment and potential development, regulatory, and sales milestones, and royalties CLEVELAND, July 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, has exercised its option to license Abeona's patented AAV204 capsid for use in potential gene therapies for a range of prevalent and rare retinal diseases that re...

July 1, 2025 1 EN
 PRESS RELEASE
Free
ABEO Abeona Therapeu...

Abeona Therapeutics® Announces New Employee Inducement Grants Under Na...

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CLEVELAND, July 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On June 30, 2025, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to 21 individuals hired by Abeona, which equity awards relate to, in the ...

July 1, 2025 1 EN
 PRESS RELEASE
Free
ABEO Abeona Therapeu...

Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 200...

Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index CLEVELAND, June 30, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it was added as a member of the U.S. small-cap Russell 2000® Index and the broad-market Russell 3000® Index as part of the reconstitution of the Russell stock indexes, effective at the open of the U.S. equity markets today. “Abeona's addition to the Russell 2000 and 3000 indexes, on the heels of ZEVASKYN™'s FDA approval, represents a pivotal moment for the company,” s...

June 30, 2025 1 EN
 PRESS RELEASE
Free
ABEO Abeona Therapeu...

Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VI...

Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa - RDEB is a lifelong debilitating, blistering skin disease associated with large and painful wounds that often remain open for years and cause significant clinical burden, including pain, itch, and risk of squamous cell carcinoma - - ZEVASKYN™ (prademagene zamikeracel) demonstrated significant wound healing and pain reduction after a single treatment with a favorable safety profile in large chronic RDEB wounds - - ZEVASKYN is the first and only autol...

June 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch